Saquinavir Inhibits the malaria parasite's chloroquine resistance transporter

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2283-2289

  Martin, Rowena E ^a   Butterworth, Alice S ^b   Gardiner, Donald L ^b,c   Kirk, Kiaran ^a   McCarthy, James S ^b,d   Skinner Adams, Tina S ^b,d  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CHLOROQUINE; CHLOROQUINE RESISTANCE TRANSPORTER; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

ARTICLE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; HETEROLOGOUS EXPRESSION; IN VITRO STUDY; MALARIA; NONHUMAN; OOCYTE; PHENOTYPE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC ORGANISM; XENOPUS LAEVIS;

ANIMALS; ANTIMALARIALS; BIOLOGICAL TRANSPORT; CHLOROQUINE; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALARIA, FALCIPARUM; MEMBRANE TRANSPORT PROTEINS; MUTATION; OOCYTES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RITONAVIR; SAQUINAVIR; TRITIUM; XENOPUS LAEVIS;

EID: 84860159977     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00166-12     Document Type: Article

References (38)

1. Allen RJ, Kirk K. 2010. Plasmodium falciparum culture: the benefits of shaking. Mol. Biochem. Parasitol. 169:63-65.
2. Andrews KT, et al. 2006. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob. Agents Chemother. 50:639-648. (Pubitemid 43190977)
3. Berenbaum MC. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130. (Pubitemid 8289152)
4. Canfield CJ, Pudney M, Gutteridge WE. 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80:373-381.
5. Djimde A, et al. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:257-263. (Pubitemid 32108530)
6. Dubar F, et al. 2011. The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem. Biol. 6:275-287.
7. Ferreira ID, Rosario VE, Cravo PV. 2006. Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes in Plasmodium falciparum. Malar. J. 5:1.
8. Fidock DA, et al. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell 6:861-871.
9. Foote SJ, et al. 1990. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 345:255-258.
10. Ford J, Khoo SH, Back DJ. 2004. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54:982-990. (Pubitemid 40136729)
11. Hasegawa J, Fujita T, Hayashi Y, Iwamoto K, Watanabe J. 1984. pKa determination of verapamil by liquid-liquid partition. J. Pharm. Sci. 73:442-445. (Pubitemid 14134314)
12. Hayward R, Saliba KJ, Kirk K. 2006. The pH of the digestive vacuole of Plasmodium falciparum is not associated with chloroquine resistance. J. Cell Sci. 119:1016-1025.
13. He Z, Chen L, You J, Qin L, Chen X. 2009. Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism. Exp. Parasitol. 123:122-127.
14. He Z, et al. 2008. Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrob. Agents Chemother. 52:2653-2656. (Pubitemid 351915702)
15. Hocart SJ, et al. 2011. 4-Aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses. Antimicrob. Agents Chemother. 55:2233-2244.
16. Kashuba AD, et al. 1999. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 43:1817-1826. (Pubitemid 29395171)
17. Kumar A, Srivastava K, Kumar SR, Puri SK, Chauhan PM. 2010. Synthesis of new 4-aminoquinolines and quinoline-acridine hybrids as antimalarial agents. Bioorg. Med. Chem. Lett. 20:7059-7063.
18. Launay O, et al. 2004. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob. Agents Chemother. 48:632-634. (Pubitemid 38141731)
19. Lehane AM, van Schalkwyk DA, Valderramos SGSG, Fidock DA, Kirk K. 2011. Differential drug efflux or accumulation does not explain variation in the chloroquine response of Plasmodium falciparum strains expressing the same isoform of mutant PfCRT. Antimicrob. Agents Chemother. 55:2310-2318.
20. Martin RE, et al. 2009. Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 325:1680-1682.
21. Nsanzabana C, Rosenthal PJ. 2011. In vitro activity of antiretroviral drugs against Plasmodium falciparum. Antimicrob. Agents Chemother. 55:5073-5077.
22. Olliaro P, Wells TN. 2009. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther. 85:584-595.
23. Parikh S, et al. 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49:2983-2985. (Pubitemid 40917621)
24. Ray S, et al. 2010. Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models. J. Med. Chem. 53:3685-3695.
25. Redmond AM, et al. 2007. Antimalarial activity of sera from subjects taking HIV protease inhibitors. AIDS 21:763-765. (Pubitemid 46568635)
26. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906-909. (Pubitemid 30130994)
27. +-ATPase. J. Biol. Chem. 274:33213-33219.
28. Sidhu AB, Valderramos SG, Fidock DA. 2005. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 57:913-926. (Pubitemid 41139856)
29. Sidhu AB, Verdier-Pinard D, Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210-213.
30. Skinner-Adams T, Davis TM. 1999. Synergistic in vitro antimalarial activity of omeprazole and quinine. Antimicrob. Agents Chemother. 43: 1304-1306. (Pubitemid 29214771)
31. Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL. 2007. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51:759-762. (Pubitemid 46185303)
32. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT. 2004. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190:1998-2000. (Pubitemid 39564706)
33. Su X, et al. 1999. A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science 286:1351-1353.
34. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
35. Ursing J, et al. 2011. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J. Infect. Dis. 203:109-116.
36. Wellems TE, et al. 1990. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 345:253-255.
37. Wlodawer A, Vondrasek J. 1998. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27:249-284. (Pubitemid 28286016)
38. Yuan J, et al. 2011. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 333:724-729.